JP2011500562A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500562A5
JP2011500562A5 JP2010528867A JP2010528867A JP2011500562A5 JP 2011500562 A5 JP2011500562 A5 JP 2011500562A5 JP 2010528867 A JP2010528867 A JP 2010528867A JP 2010528867 A JP2010528867 A JP 2010528867A JP 2011500562 A5 JP2011500562 A5 JP 2011500562A5
Authority
JP
Japan
Prior art keywords
alkyl
alkenyl
compound according
compound
ring members
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010528867A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500562A (ja
JP5591706B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/011422 external-priority patent/WO2009048527A1/en
Publication of JP2011500562A publication Critical patent/JP2011500562A/ja
Publication of JP2011500562A5 publication Critical patent/JP2011500562A5/ja
Application granted granted Critical
Publication of JP5591706B2 publication Critical patent/JP5591706B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010528867A 2007-10-10 2008-10-03 置換ビフェニルgpr40調節因子 Expired - Fee Related JP5591706B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US99878607P 2007-10-10 2007-10-10
US60/998,786 2007-10-10
US6872408P 2008-03-06 2008-03-06
US61/068,724 2008-03-06
PCT/US2008/011422 WO2009048527A1 (en) 2007-10-10 2008-10-03 Substituted biphenyl gpr40 modulators

Publications (3)

Publication Number Publication Date
JP2011500562A JP2011500562A (ja) 2011-01-06
JP2011500562A5 true JP2011500562A5 (enExample) 2011-11-17
JP5591706B2 JP5591706B2 (ja) 2014-09-17

Family

ID=40338063

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010528867A Expired - Fee Related JP5591706B2 (ja) 2007-10-10 2008-10-03 置換ビフェニルgpr40調節因子

Country Status (19)

Country Link
US (1) US8030354B2 (enExample)
EP (1) EP2205548A1 (enExample)
JP (1) JP5591706B2 (enExample)
KR (1) KR20100090249A (enExample)
CN (1) CN102083783A (enExample)
AR (1) AR068840A1 (enExample)
AU (1) AU2008311355B2 (enExample)
BR (1) BRPI0818253A2 (enExample)
CA (1) CA2702047C (enExample)
CL (1) CL2008002997A1 (enExample)
CO (1) CO6270312A2 (enExample)
CR (1) CR11420A (enExample)
IL (1) IL204635A0 (enExample)
MA (1) MA31841B1 (enExample)
MX (1) MX2010003876A (enExample)
PE (1) PE20091222A1 (enExample)
TN (1) TN2010000125A1 (enExample)
TW (1) TW200927091A (enExample)
WO (1) WO2009048527A1 (enExample)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101868452B (zh) 2007-10-10 2014-08-06 诺华股份有限公司 螺环吡咯烷类与其对抗hcv和hiv感染的应用
EP2260017A1 (en) * 2008-03-06 2010-12-15 Amgen, Inc Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
CA2739888C (en) * 2008-10-15 2013-11-19 Amgen Inc. Spirocyclic gpr40 modulators
AR074760A1 (es) 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EA201290574A1 (ru) 2009-12-25 2012-12-28 Мотида Фармасьютикал Ко., Лтд. Новое производное 3-гидрокси-5-арилизотиазола
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2582674B1 (en) * 2010-06-16 2014-10-01 Cymabay Therapeutics, Inc. Gpr120 receptor agonists and uses thereof
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
US9040525B2 (en) 2010-10-08 2015-05-26 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
CN102617501A (zh) * 2011-01-31 2012-08-01 中国科学院上海药物研究所 取代正戊酰胺类化合物、其制备方法及用途
CN105153146A (zh) 2011-04-27 2015-12-16 持田制药株式会社 新的3-羟基异噻唑1-氧化物衍生物
EP2716636A4 (en) 2011-04-28 2014-11-26 Mochida Pharm Co Ltd CYCLIC AMIDE DERIVATIVE
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP6095580B2 (ja) 2012-02-13 2017-03-15 武田薬品工業株式会社 芳香環化合物
EP2816032A4 (en) * 2012-02-13 2015-09-30 Takeda Pharmaceutical AROMATIC RING CONNECTION
RU2014138894A (ru) * 2012-02-28 2016-04-20 Пирамал Энтерпрайзис Лимитед Производные фенилалкановой кислоты в качестве агонистов gpr
EP2872127A1 (en) 2012-07-11 2015-05-20 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
EP2880028B1 (en) 2012-08-02 2020-09-30 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
KR101942752B1 (ko) * 2012-11-05 2019-01-28 주식회사 엘지화학 Gpr120 효능제로서의 티오아릴 유도체
CN104812748B (zh) 2012-11-16 2017-10-24 百时美施贵宝公司 二氢吡唑gpr40调节剂
EP2958562B1 (en) 2013-02-22 2025-09-10 Merck Sharp & Dohme LLC Antidiabetic bicyclic compounds
JP2016520517A (ja) * 2013-03-14 2016-07-14 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company ビシクロ[2.2.1]酸のgpr120モジュレーター
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
KR101569522B1 (ko) * 2013-04-18 2015-11-17 현대약품 주식회사 신규한 3-(4-(벤질옥시)페닐)헥스-4-이노익 산 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 대사성 질환의 예방 또는 치료용 약학적 조성물
WO2015020184A1 (ja) 2013-08-09 2015-02-12 武田薬品工業株式会社 芳香環化合物
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
KR20160077213A (ko) 2013-11-14 2016-07-01 카딜라 핼쓰캐어 리미티드 새로운 헤테로시클릭 화합물
WO2015073342A1 (en) 2013-11-15 2015-05-21 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015084692A1 (en) 2013-12-04 2015-06-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
EP3177282B1 (en) 2014-08-08 2021-10-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
EP3177287B1 (en) 2014-08-08 2022-02-23 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3558298A4 (en) 2016-12-20 2020-08-05 Merck Sharp & Dohme Corp. ANTIDIABETIC SPIROCHROMAN COMPOUNDS
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
MX2020008404A (es) 2018-02-13 2020-09-25 Gilead Sciences Inc Inhibidores de molecula de muerte programada 1 (pd-1)/ligando de molecula de muerte programada 1 (pd-l1).
ES3035911T3 (en) 2018-04-19 2025-09-11 Gilead Sciences Inc Pd-1/pd-l1 inhibitors
SI3820572T1 (sl) 2018-07-13 2023-12-29 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
JP7158577B2 (ja) 2018-10-24 2022-10-21 ギリアード サイエンシーズ, インコーポレイテッド Pd-1/pd-l1阻害剤
WO2020197926A1 (en) * 2019-03-22 2020-10-01 Kallyope, Inc. Gpcr combination therapies
CN115667277A (zh) 2020-02-28 2023-01-31 卡尔优普公司 Gpr40激动剂
CN116472273A (zh) * 2020-08-05 2023-07-21 宁康瑞珠生物制药(珠海)有限公司 抗糖尿病化合物和组合物
CN118679158A (zh) * 2022-01-14 2024-09-20 宁康瑞珠生物制药(珠海)有限公司 抗糖尿病化合物和组合物
EP4600246A4 (en) 2022-10-03 2026-01-07 Public Univ Corp Yokohama City Univ BICYCLIC IMIDAZOPYRIDINE DERIVATIVES
EP4662209A1 (en) * 2023-02-07 2025-12-17 Rezubio Pharmaceuticals Co., Ltd Conjugate compounds and compositions
WO2024188313A1 (zh) * 2023-03-14 2024-09-19 凯思凯迪(上海)医药科技有限公司 苯并杂环类化合物、其制备方法和其应用
CN117603029B (zh) * 2023-11-21 2025-12-19 江苏禾本生化有限公司 一种戊菌唑关键中间体的合成方法

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE305216B (enExample) 1965-09-17 1968-10-21 Astra Apotekarnes Kem Fab
FR2359135A1 (fr) 1976-07-22 1978-02-17 Hexachimie Nouvelles phenoxyhydroxypropylamines, procede pour les preparer et leur application en therapeutique
US4760089A (en) 1985-09-09 1988-07-26 Smithkline Beckman Corporation Irreversible dopamine-β-hydroxylase inhibitors
DK303887A (da) 1986-06-19 1987-12-20 Smithkline Beckman Corp Dopamin-beta-hydroxylaseinhibitorer og fremgangsmaade til fremstilling deraf
GB8917069D0 (en) 1989-07-26 1989-09-13 Merck Sharp & Dohme Therapeutic agents
DE4019307A1 (de) 1990-06-16 1991-12-19 Bayer Ag 2-methoximinocarbonsaeureester
AU668181B2 (en) 1992-05-20 1996-04-26 Merck & Co., Inc. Ester derivatives of 4-aza-steroids
JPH07508038A (ja) 1992-05-20 1995-09-07 メルク エンド カンパニー インコーポレーテッド 4−アザステロイドの17−エーテル及びチオエーテル
DE4241632A1 (de) 1992-12-10 1994-06-16 Thomae Gmbh Dr K Carbonsäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
WO1995001326A1 (en) 1993-06-30 1995-01-12 The Wellcome Foundation Limited Anti-atherosclerotic diaryl compounds
US5463063A (en) 1993-07-02 1995-10-31 Celgene Corporation Ring closure of N-phthaloylglutamines
AU6490396A (en) 1995-07-14 1997-02-18 Smithkline Beecham Corporation Substituted-pent-4-ynoic acids
US5795900A (en) 1995-10-03 1998-08-18 Abbott Laboratories Symmetrical bis-heteroaryl-methoxy-phenylalkyl carboxylates as inhibitors of leukotriene biosynthesis
JPH10316641A (ja) 1997-03-14 1998-12-02 Sankyo Co Ltd カルボン酸誘導体
AU8750298A (en) 1997-08-28 1999-03-22 Ono Pharmaceutical Co. Ltd. Peroxisome proliferator-activated receptor controllers
US6645939B1 (en) 1997-11-24 2003-11-11 Merck & Co., Inc. Substituted β-alanine derivatives as cell adhesion inhibitors
WO1999046232A1 (en) * 1998-03-10 1999-09-16 Ono Pharmaceutical Co., Ltd. Carboxylic acid derivatives and drugs containing the same as the active ingredient
DE19941567A1 (de) 1998-09-05 2000-04-20 Merck Patent Gmbh Neue flüssigkristalline Verbindungen
WO2000063196A1 (en) 1999-04-20 2000-10-26 Novo Nordisk A/S New compounds, their preparation and use
ATE263162T1 (de) 1999-05-05 2004-04-15 Aventis Pharma Ltd Harnstoffderivate und ihr gebrauch als zell adhesion modulatoren
GB9914977D0 (en) 1999-06-25 1999-08-25 Glaxo Group Ltd Chemical compounds
GB9927056D0 (en) 1999-11-17 2000-01-12 Karobio Ab Thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
AU1624801A (en) 1999-11-19 2001-05-30 Corvas International, Inc. Plasminogen activator inhibitor antagonists related applications
JP2001242165A (ja) 2000-02-25 2001-09-07 Dai Ichi Seiyaku Co Ltd 採血用試薬
JP2002003368A (ja) 2000-06-23 2002-01-09 Saitama Daiichi Seiyaku Kk 経皮吸収又は経粘膜吸収用の製剤
GB0031107D0 (en) 2000-12-20 2001-01-31 Glaxo Group Ltd Chemical compounds
GB0031527D0 (en) 2000-12-22 2001-02-07 Smithkline Beecham Plc New use
US6906046B2 (en) 2000-12-22 2005-06-14 Celltech R & D Inc. Pharmaceutical uses and synthesis of benzobicyclooctanes
CA2433573A1 (en) 2000-12-28 2002-07-11 Takeda Chemical Industries, Ltd. Alkanoic acid derivatives, process for their production and use thereof
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
ATE345128T1 (de) 2001-06-07 2006-12-15 Lilly Co Eli Modulatoren der peroxisom-proliferator- aktivierten rezeptoren (ppar)
CN1293042C (zh) 2002-02-07 2007-01-03 远藤仁 芳香族氨基酸衍生物及其药物组合物
DE60332320D1 (de) 2002-02-14 2010-06-10 Takeda Pharmaceutical Neues screening-verfahren
US20030207924A1 (en) 2002-03-07 2003-11-06 Xue-Min Cheng Compounds that modulate PPAR activity and methods of preparation
US6875780B2 (en) 2002-04-05 2005-04-05 Warner-Lambert Company Compounds that modulate PPAR activity and methods for their preparation
CA2487315A1 (en) 2002-05-24 2003-12-04 Takeda Pharmaceutical Company Limited 1,2-azole derivatives with hypoglycemic and hypolipidemic activity
GB0214149D0 (en) 2002-06-19 2002-07-31 Glaxo Group Ltd Chemical compounds
US7553867B2 (en) 2002-09-06 2009-06-30 Takeda Pharmaceutical Company Limited Furan or thiophene derivative and medicinal use thereof
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
JP4594611B2 (ja) * 2002-11-08 2010-12-08 武田薬品工業株式会社 受容体機能調節剤
WO2004092117A1 (en) 2003-04-07 2004-10-28 Kalypsys, Inc. Para-sulfonyl substituted phenyl compounds as modulators of ppars
CA2527691C (en) 2003-05-30 2013-01-22 Takeda Pharmaceutical Company Limited Condensed ring compound
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
EP1697333A4 (en) 2003-12-17 2009-07-08 Merck & Co Inc (3,4-DISUBSTITUTED) PROPANE ACID BOXYLATES AS AGONISTS OF THE S1P (EDG) RECEPTOR
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 3−(4−ベンジルオキシフェニル)プロパン酸誘導体
US7585880B2 (en) 2003-12-26 2009-09-08 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
WO2005080367A1 (en) 2004-02-12 2005-09-01 Pharmagene Laboratories Limited Ep2 receptor agonists
BRPI0508098A (pt) 2004-02-27 2007-07-17 Amgen Inc compostos, composições farmacêuticas e métodos para uso no tratamento de distúrbios metabólicos
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP2253315A1 (en) * 2004-03-30 2010-11-24 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
WO2005118542A1 (en) * 2004-05-28 2005-12-15 Eli Lilly And Company Glucagon receptor antagonists, preparation and therapeutic uses
JP2007269630A (ja) 2004-06-23 2007-10-18 Toudai Tlo Ltd インスリン分泌促進剤
US20060003344A1 (en) 2004-06-30 2006-01-05 Pfizer Inc. Methods related to a single nucleotide polymorphism of the G protein coupled receptor, GPR40
JP2007284350A (ja) 2004-07-27 2007-11-01 Takeda Chem Ind Ltd 糖尿病治療剤
CA2593788A1 (en) 2005-01-28 2006-08-10 Merck And Co., Inc. Antidiabetic bicyclic compounds
ATE440091T1 (de) 2005-01-31 2009-09-15 Merck & Co Inc Antidiabetische bicyclische verbindungen
US7465804B2 (en) 2005-05-20 2008-12-16 Amgen Inc. Compounds, pharmaceutical compositions and methods for their use in treating metabolic disorders
WO2007008541A2 (en) 2005-07-08 2007-01-18 Kalypsys, Inc. Cellular cholesterol absorption modifiers
JP5084503B2 (ja) 2005-07-29 2012-11-28 武田薬品工業株式会社 シクロプロパンカルボン酸化合物
CA2621949A1 (en) 2005-09-14 2007-03-22 Amgen Inc. Conformationally constrained 3- (4-hydroxy-phenyl) - substituted-propanoic acids useful for treating metabolic disorders
WO2007049050A2 (en) 2005-10-27 2007-05-03 Heptahelix Ab Modulators of gpr40 for the treatment of diabetes
AU2007225208A1 (en) 2006-03-14 2007-09-20 Amgen Inc. Bicyclic carboxylic acid derivatives useful for treating metabolic disorders
TW200815377A (en) 2006-04-24 2008-04-01 Astellas Pharma Inc Oxadiazolidinedione compound
DE102006021872B4 (de) 2006-05-11 2008-04-17 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-oxy oder -mercapto substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021874B4 (de) 2006-05-11 2008-03-27 Sanofi-Aventis 4,5-Diphenyl-pyrimidinyl-amino substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
DE102006021878A1 (de) 2006-05-11 2007-11-15 Sanofi-Aventis Phenylamino-benzoxazol substituierte Carbonsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
JP5271895B2 (ja) 2006-05-15 2013-08-21 メルク・シャープ・アンド・ドーム・コーポレーション 抗糖尿病性の二環式化合物
RU2444521C2 (ru) 2006-06-27 2012-03-10 Такеда Фармасьютикал Компани Лимитед Конденсированные циклические соединения
WO2008030618A1 (en) 2006-09-07 2008-03-13 Amgen Inc. Benzo-fused compounds for use in treating metabolic disorders
EP2064193A1 (en) 2006-09-07 2009-06-03 Amgen, Inc Heterocyclic gpr40 modulators
JP2010508268A (ja) 2006-10-31 2010-03-18 メルク エンド カムパニー インコーポレーテッド 抗糖尿病二環式化合物
WO2008130514A1 (en) 2007-04-16 2008-10-30 Amgen Inc. Substituted biphenyl phenoxy-, thiophenyl- and aminophenylpropanoic acid gpr40 modulators

Similar Documents

Publication Publication Date Title
JP2011500562A5 (enExample)
RU2477723C2 (ru) Ингибиторы протеинкиназ (варианты), их применение для лечения онкологических заболеваний и фармацевтическая композиция на их основе
JP2012505896A5 (enExample)
KR101454936B1 (ko) Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한 화합물 및 방법
KR102122357B1 (ko) 설파모일-아릴아미드 및 b형 간염 치료제로서의 그 용도
DE60218511T2 (de) Dihydroxypyrimidin-carbonsäueramid-hemmer der hiv-integrase
TWI712595B (zh) 三環性螺化合物
KR102534262B1 (ko) 헤테로환형 유도체 및 이의 용도
CA2923184A1 (en) Compounds useful as immunomodulators
JP2016505536A5 (enExample)
JP2009537524A5 (enExample)
JP2013512277A5 (enExample)
WO2006038594A1 (ja) N型カルシウムチャネル阻害薬
JP2021533110A (ja) 癌免疫療法剤としての新規エクトヌクレオチドピロホスファターゼ/ホスホジエステラーゼ−1(ENPP1)の置換3H−イミダゾ[4,5−c]ピリジンおよび1H−ピロロ[2,3−c]ピリジンシリーズならびにインターフェロン遺伝子刺激因子(STING)調節剤
JP2018515495A5 (enExample)
AR056155A1 (es) Antagonistas del receptor 1 de la hormona de concentracion de melanina no basica
WO2007129745A1 (ja) ヘテロアリールアミド低級カルボン酸誘導体
CA3020310A1 (en) Pyrrolo[1,2-a]pyrimidinyl carboxamide compounds and their use in the treatment of medical disorders
JP2018528159A (ja) 芳香族スルホンアミド誘導体
JP2019059781A5 (enExample)
ES2729525T3 (es) Nuevo método para sintetizar un intermedio de Rivaroxaban, 4-{4-[(5S)-5-(aminometil)-2-oxo-1,3-oxazolidin-3-il]fenil]}morfolin-3-ona
CN105085429A (zh) 芳杂环类衍生物及其在药物上的应用
JP2015502371A5 (enExample)
KR101373911B1 (ko) Bcl 단백질과 결합 파트너의 상호작용을 억제하기 위한화합물 및 방법
RU2009148821A (ru) Производные [1,10]фенантролина для лечения нейродегенеративных или гематологических заболеваний